Abstract
Purpose: Reteplase, a recombinant tissue plasminogen activator, has been used in the treatment of acute coronary occlusion. Experience is accumulating regarding its use in the treatment of peripheral vascular disease. Increased experience with this thrombolytic agent may show that it can be an appropriate alternative agent to currently employed plasminogen activators.
Materials and Methods: Over the course of six months, reteplase was used to treat 18 patients with peripheral arterial occlusions, confined to the lower extremities. The agent was infused via “pulse-spray” catheters. Fifteen patients were started on 0.5 U/h. Concurrent heparin therapy was used at 500 U/h in 16 of 18 patients.
Results: The average total dose of reteplase infused was 13.3 units. It ranged from 6.2 to 41.5 units. The average duration of infusion was 26.9 hours with a range of 12–44 hours. Clinical success, defined as restoration of sufficient patency to reestablish limb function and resolution of pain in the symptomatic extremity was 89% (16 out of 18).
Hemorrhagic complications occurred in five patients and were major in one patient (5%). No patient experienced intracranial hemorrhage.
Conclusion: Increased experience with the use of reteplase in the treatment of acute lower extremity occlusions is accumulating. The safety and efficacy profile in our group appears satisfactory and compares to other studies. However, definite conclusions must await the results of controlled comparisons of different reteplase infusion regimens and controlled comparison to other thrombolytic agents.
Similar content being viewed by others
References
Goldhaber SZ. Thrombolytic therapy. Adv Intern Med1999;44:311–325.
Ouriel K. Thrombolytic therapy in peripheral vascular disease. Adv Surg1996;29:191–206.
Tomera JF, Kaul AF. Regional thrombolytic infusion for peripheral arterial occlusion and deep vein thrombosis: tried and true. Am J Health-Syst Pharm1997;54:1988–1991.
Ouriel K, Veith FJ, Sasahara AA, for the Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med1998;338:1105–1111.
Porter JM. Thrombolysis for acute arterial occlusion of the legs [editorial]. N Engl J Med1998;338:1148–1150.
Ouriel K, Shortell CK, DeWeese JA, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. JVS1994;19:1021–1030.
McNamara T, Bumberger R, Merchant R. Intraarterial urokinase as the initial therapy for acutely ischemic lower limbs. Circulation1991;83(Suppl I):I--106–I--119.
Smalling RW, Hanna GP. Clinical pharmacology and mechanisms of action of thrombolytic agents. Am J Cardiol1996:9–15.
Weaver WD. The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials. Eur Heart J1996;17(SupplF):9–15.
Laird JR, Dangas G, Jaff M, et al. Intra-arterial reteplase for the treatment of acute limb ischemia. J Invas Cardiol1999;11:757–762.
Cho KJ, Recinella BS. Pattern of dispersion from a pulse spray catheter for delivery of thrombolytic agents: design, theory and results. Acad Radiol1997;4:210–216.
Ouriel K, Gray B, Clair DG, Ohn J. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis. JVIR2000;11:295–298.
Ouriel K, Katzen B, Mewissen M, et al. Reteplase in the treatment of peripheral arterial and venous occlusions: a pilot study. J Vasc Inter Radiol2000;11(7):849–854.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kiproff, P.M., Yammine, K., Potts, J.M. et al. Reteplase Infusion in the Treatment of Acute Lower Extremity Occlusions. J Thromb Thrombolysis 13, 75–79 (2002). https://doi.org/10.1023/A:1016290629256
Issue Date:
DOI: https://doi.org/10.1023/A:1016290629256